BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

239 related articles for article (PubMed ID: 33963009)

  • 41. Enterovirus A71 Oncolysis of Malignant Gliomas.
    Zhang X; Wang H; Sun Y; Qi M; Li W; Zhang Z; Zhang XE; Cui Z
    Mol Ther; 2020 Jun; 28(6):1533-1546. PubMed ID: 32304669
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Combination immunotherapy using G-CSF and oncolytic virotherapy reduces tumor growth in osteosarcoma.
    Morales-Molina A; Gambera S; Leo A; García-Castro J
    J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33737338
    [TBL] [Abstract][Full Text] [Related]  

  • 43. A novel apoptotic mechanism of genetically engineered adenovirus-mediated tumour-specific p53 overexpression through E1A-dependent p21 and MDM2 suppression.
    Yamasaki Y; Tazawa H; Hashimoto Y; Kojima T; Kuroda S; Yano S; Yoshida R; Uno F; Mizuguchi H; Ohtsuru A; Urata Y; Kagawa S; Fujiwara T
    Eur J Cancer; 2012 Sep; 48(14):2282-91. PubMed ID: 22244827
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The in vivo therapeutic efficacy of the oncolytic adenovirus Delta24-RGD is mediated by tumor-specific immunity.
    Kleijn A; Kloezeman J; Treffers-Westerlaken E; Fulci G; Leenstra S; Dirven C; Debets R; Lamfers M
    PLoS One; 2014; 9(5):e97495. PubMed ID: 24866126
    [TBL] [Abstract][Full Text] [Related]  

  • 45. A novel Golgi protein (GOLPH2)-regulated oncolytic adenovirus exhibits potent antitumor efficacy in hepatocellular carcinoma.
    Wang Y; Liu T; Huang P; Zhao H; Zhang R; Ma B; Chen K; Huang F; Zhou X; Cui C; Liu X
    Oncotarget; 2015 May; 6(15):13564-78. PubMed ID: 25980438
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Biosilicified oncolytic adenovirus for cancer viral gene therapy.
    Kong H; Zhao R; Zhang Q; Iqbal MZ; Lu J; Zhao Q; Luo D; Feng C; Zhang K; Liu X; Kong X
    Biomater Sci; 2020 Oct; 8(19):5317-5328. PubMed ID: 32779647
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Potent antitumor effect of neurotensin receptor-targeted oncolytic adenovirus co-expressing decorin and Wnt antagonist in an orthotopic pancreatic tumor model.
    Na Y; Choi JW; Kasala D; Hong J; Oh E; Li Y; Jung SJ; Kim SW; Yun CO
    J Control Release; 2015 Dec; 220(Pt B):766-82. PubMed ID: 26471393
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Dual E1A oncolytic adenovirus: targeting tumor heterogeneity with two independent cancer-specific promoter elements, DF3/MUC1 and hTERT.
    Doloff JC; Jounaidi Y; Waxman DJ
    Cancer Gene Ther; 2011 Mar; 18(3):153-66. PubMed ID: 20865021
    [TBL] [Abstract][Full Text] [Related]  

  • 49. An armed, YB-1-dependent oncolytic adenovirus as a candidate for a combinatorial anti-glioma approach of virotherapy, suicide gene therapy and chemotherapeutic treatment.
    Kostova Y; Mantwill K; Holm PS; Anton M
    Cancer Gene Ther; 2015 Jan; 22(1):30-43. PubMed ID: 25501992
    [TBL] [Abstract][Full Text] [Related]  

  • 50. A chimeric adenovirus with an Ad 3 fiber knob modification augments glioma virotherapy.
    Nandi S; Ulasov IV; Rolle CE; Han Y; Lesniak MS
    J Gene Med; 2009 Nov; 11(11):1005-11. PubMed ID: 19688792
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Silencing of Mcl-1 overcomes resistance of melanoma cells against TRAIL-armed oncolytic adenovirus by enhancement of apoptosis.
    Tolksdorf B; Zarif S; Eberle J; Hazini A; Dieringer B; Jönsson F; Kreppel F; Kurreck J; Fechner H
    J Mol Med (Berl); 2021 Sep; 99(9):1279-1291. PubMed ID: 34028599
    [TBL] [Abstract][Full Text] [Related]  

  • 52. A novel oncolytic adenovirus targeting Wnt signaling effectively inhibits cancer-stem like cell growth via metastasis, apoptosis and autophagy in HCC models.
    Zhang J; Lai W; Li Q; Yu Y; Jin J; Guo W; Zhou X; Liu X; Wang Y
    Biochem Biophys Res Commun; 2017 Sep; 491(2):469-477. PubMed ID: 28698142
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Systemic Delivery of Oncolytic Adenovirus to Tumors Using Tumor-Infiltrating Lymphocytes as Carriers.
    Santos J; Heiniö C; Quixabeira D; Zafar S; Clubb J; Pakola S; Cervera-Carrascon V; Havunen R; Kanerva A; Hemminki A
    Cells; 2021 Apr; 10(5):. PubMed ID: 33922052
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Overexpression of tumor suppressor TSLC1 by a survivin-regulated oncolytic adenovirus significantly inhibits hepatocellular carcinoma growth.
    He G; Lei W; Wang S; Xiao R; Guo K; Xia Y; Zhou X; Zhang K; Liu X; Wang Y
    J Cancer Res Clin Oncol; 2012 Apr; 138(4):657-70. PubMed ID: 22237452
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Intravenous injection of oncolytic picornavirus SVV-001 prolongs animal survival in a panel of primary tumor-based orthotopic xenograft mouse models of pediatric glioma.
    Liu Z; Zhao X; Mao H; Baxter PA; Huang Y; Yu L; Wadhwa L; Su JM; Adesina A; Perlaky L; Hurwitz M; Idamakanti N; Police SR; Hallenbeck PL; Hurwitz RL; Lau CC; Chintagumpala M; Blaney SM; Li XN
    Neuro Oncol; 2013 Sep; 15(9):1173-85. PubMed ID: 23658322
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Viruses, gene therapy and stem cells for the treatment of human glioma.
    Kyritsis AP; Sioka C; Rao JS
    Cancer Gene Ther; 2009 Oct; 16(10):741-52. PubMed ID: 19644531
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Pharmacokinetic study of neural stem cell-based cell carrier for oncolytic virotherapy: targeted delivery of the therapeutic payload in an orthotopic brain tumor model.
    Thaci B; Ahmed AU; Ulasov IV; Tobias AL; Han Y; Aboody KS; Lesniak MS
    Cancer Gene Ther; 2012 Jun; 19(6):431-42. PubMed ID: 22555507
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Augmenting the antitumor effect of TRAIL by SOCS3 with double-regulated replicating oncolytic adenovirus in hepatocellular carcinoma.
    Wei RC; Cao X; Gui JH; Zhou XM; Zhong D; Yan QL; Huang WD; Qian QJ; Zhao FL; Liu XY
    Hum Gene Ther; 2011 Sep; 22(9):1109-19. PubMed ID: 21361790
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Engager T cells: a new class of antigen-specific T cells that redirect bystander T cells.
    Iwahori K; Kakarla S; Velasquez MP; Yu F; Yi Z; Gerken C; Song XT; Gottschalk S
    Mol Ther; 2015 Jan; 23(1):171-8. PubMed ID: 25142939
    [TBL] [Abstract][Full Text] [Related]  

  • 60. A novel capsid-modified oncolytic recombinant adenovirus type 5 for tumor-targeting gene therapy by intravenous route.
    Wang Z; Yu B; Wang B; Yan J; Feng X; Wang Z; Wang L; Zhang H; Wu H; Wu J; Kong W; Yu X
    Oncotarget; 2016 Jul; 7(30):47287-47301. PubMed ID: 27323824
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.